Peregrine: Phospholipid-targeted antibodies fused with cytokines reduce tumors

By Elaine Rigoli

Tampa, Fla., Sept. 19 - Peregrine Pharmaceuticals, Inc. reported new research showing that a fusion protein approach that combines two proprietary Peregrine technology platforms - its Vascular Targeting Agent (VTA) and anti-phospholipid (anti-PS) technologies - has demonstrated significant anti-tumor potential.

In a presentation at the Angiogenesis and Vascular Targeting Agents Conference, researchers presented data showing that a fusion protein combining an antibody from Peregrine's anti-phospholipid therapy program with immunostimulatory cytokines such as interferon or interleukin reduced tumor growth in animal cancer models by more than 90%, with no discernable increase in toxicity.

The Tustin, Calif., biopharmaceutical company said these studies represent an important validation of a new class of compounds in Peregrine's proprietary VTA platform, which uses agents targeted to tumor blood vessels to kill tumors by depriving them of the nutrients and oxygen needed for continued growth.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.